McMaster University

McMaster University

Morris A. Blajchman

, MD, FRCPC

Professor Emeritus
Pathology and Molecular Medicine

Professor Emeritus, Medicine
McMaster University
blajchma@mcmaster.ca

Morris A. Blajchman

Faculty Biography

Education and Professional Standing

BSc, McGill University, with Distinction1960
MD, McGill University, 1964
FRCPC, Internal Medicine, 1968
FRCPC, Hematology, 1970

Interests

Research and Clinical Focus

Dr. Blajchman qualified as a physician in 1964 at McGill University in Montreal, Canada.  His post-graduate training was in internal medicine at the Graduate Hospital of the University of Pennsylvania and in hematology at the Royal Postgraduate Medical School in London, England.  The latter was with the illustrious haematologist Sir John Dacie.  Dr. Blajchman has been a member of the Faculty at McMaster University since 1970, where he is currently Emeritus Professor in both the Departments of Medicine and Pathology.  He is also currently Medical Director of the Southern Ontario Centres (Hamilton and London) of Canadian Blood Services. 

Most recently (September 2007) the National Heart, Lung, and Blood Institute (NHLBI) in the United States appointed Dr. Blajchman as Chairman of the Transfusion Medicine and Hemostasis Clinical Trials Network (TMH CTN).  The Network is comprised of seventeen clinical centres in the U.S. and a data coordinating centre.  The goal of the TMH CTN is to design and perform multi-center clinical trials comparing management strategies of potential benefit for children and adults with hemostatic disorders and to evaluate novel and existing blood component therapies for the treatment of hematologic disorders.  As Chairman of the Network, Dr. Blajchman will lead the TMH CTN Executive Committee and Steering Committee. 

Dr. Blajchman remains active in research relating to various aspects of Transfusion Medicine and hemostasis including: the investigation of the hemostatic function of novel platelet products and substitutes; the study of immunomodulatory aspects of allogenic blood transfusions; the evaluation of the significance of bacteria in the blood supply; the investigation of transfusion requirements and alternatives to transfusion in critical care patients; and the exploration of structural-functional relationships of various clotting factors.  Dr. Blajchman has published or has in press over 370 articles and book chapters relating to his academic interests in both Transfusion Medicine and hemostasis.  He is the co-author or co-editor of three books relating to Transfusion Medicine issues.  In 2002 Dr. Blajchman became the Section Editor for the Transfusion section of the hematology website known as BloodMed.com, coordinated by Blackwell Scientific Publishing.  Finally, he is the founding and current editor of the journal Transfusion Medicine Reviews, which in January of 2009 began its twenty-third year of publication. 

Dr. Blajchman in his more than 30-year career has received many awards and honours.  These include: in 2003, a Lifetime Achievement Award from Canadian Blood Services; in 2004, the Foundation Lectureship for the Royal College of Pathologists, London, England, and the Emily Cooley Award and Lectureship presented at the 2004 Annual Meeting of the AABB in Baltimore, Maryland. 


Team Members

Laboratory Staff: Myron Kulczycky

Selected Publications

  • Lee, DH, Blajchman, MA. Platelet Substitutes and Novel Methods of Platelet Preservation. In: Platelets, 2nd Edition.  Michelson AD (Ed). Elsevier San Diego, CA. 2007; pp 1297-1309.
  • Ramirez-Arcos S, Goldman M, Blajchman MA. Bacterial Infections. In: Blood Banking and Transfusion Medicine, 2nd Edition.  Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD (Eds). Churchill Livingstone/Elsevier, Philadelphia, PA. 2007; pp 639-651.
  • Webert KE, Kleinman SH, Blajchman MA. Transfusion-Related Acute Lung Injury (TRALI). In: Blood Banking and Transfusion Medicine, 2nd Edition. Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD (Eds). Churchill Livingstone/Elsevier, Philadelphia, PA. 2007; pp 691-700.
  • Lee DH, Blajchman MA. Animal Models. In: Platelets, 2nd Edition. Michelson AD (Ed). Elsevier, San Diego, CA. 2007; pp 587-610.
  • Ramirez-Arcos S, Goldman M, Blajchman MA. Bacterial Contamination. In: Transfusion Reactions, 3rd Edition. Popovsky M (Ed). AABB Press, Bethesda, MD. 2007; pp 163-206.
  • McDonald CP, Blajchman MA. Bacteiral contamination in blood and blood components. In: Transfusion Microbiology. Barbara JA, Regan FAM, Contreras MC (Eds). Cambridge University Press, Cambridge, UK. 2008; pp 87-115.
  • Blajchman MA, Vamvakas EC. Transfusion-related immunomodulation. In: Practical Transfusion Medicine, 3rd Edition. Murphy M, Pamphilon D (Eds). Wiley InterScience. 2009, pp 98-106.
  • Vamvakas EC, Bordin JO, Blajchman MA. Immunomodulatory and proinflammatory effects of allogenic blood transfusion. In: Rossi’s Principles of Transfusion Medicine, 4th Edition. Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG, Petrides M (Eds). Wiley-Blackwell and AABB Press. 2009.
  • Arnold DM, Blajchman MA, DiTomasso J, Kulczycki M, Keith P.  Passive transfer of peanut hypersensitivity by frozen plasma transfusion. Archives of Internal Medicine. 2007; 167: 853-854.
  • Vamvakas EC, Blajchman MA. Transfusion-related Immunomodulation (TRIM): An Update. Blood Reviews. 2007; 21: 327-348.
  • Clark DA, Gorczynski RM, Blajchman MA.  Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signalling molecule and alloantigen.  Transfusion. 2008; 48: 814-821.
  • Webert KE, Cook RJ, Couban S, Carruthers J, Lee KA, Blajchman MA, Lipton JH, Brandwein JM, Heddle, NM. A multicenter pilot randomized control trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion 2008; 48: 81-91.
  • Webert KE, Cserti CM, Hannon J, Lin, Y, Pavenski K, Prendergrast JM, Blajchman MA.  Proceedings of a consensus conference: Pathogen inactivation – Making decisions about new technologies. Transfusion Medicine Reviews. 2008; 22: 1-34.
  • Bassuni WF, Blajchman MA, Al-Mosharya MA.  Why implement universal leukoreducion? Hematology/Oncology and Stem Cell Therapy. 2008; 1: 106-123.
  • Clark DA, Wong K, Barvatt D, Chan Z, Liu J, Lee L, Gorczynski RM, Blajchman MA.  CD200-dependant and non-CD200-dependent pathways of NK cell suppression by human IVIG. J. Assist. Reprod. Genet. 2008; 25: 67-72.
  • Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Guke PC, Arellano R, Blajchman MA, Buzzières JA, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. A clinical trial comparing aprotinin with lysine analogues in high-risk cardiac surgery. New Engl. J. Med. 2008; 358: 2319-2331.
  • Blajchman MA, Slichter SJ, Heddle NM, Murphy MF.  New strategies for the optimal use of platelet transfusions. Hematology. 2008, 198-204.
  • Whyte RK, Kirpalani H, Asztalos EV, Andersen C, Blajchman MA, Heddle NM, LACorte M, Robertson CM, Clarke MC, Vincer KJ, Doyle LW, Roberts RS, & PINTOS Study Group.  Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal haemoglobin thresholds for blood transfusion. Pediatrics. 2009; 123: 207-213.
  • Fergusson D, Hutton B, Hogan DL, LeBel L, Blajchman MA, Ford JC, Hebert P, Kakadekar A, Kovacs L, Lee S, Sankaran K, Shapiro S, Smyth JA, Ramesh K, Bouali NR, Tinmouth A, Walker R.  The age of red blood cells in premature infants (ARIPI) randomized controlled trial: Study design. Transfus Med Rev. 2009; 23: 55-61.
  • Klein H, Glynn SA, Ness A, Blajchman MA. Research opportunities for pathogen reduction/inactivation of blood components: Summary of an NHLBI Workshop. Transfusion. 2009; In Press.
  • Vamvakas EC, Blajchman MA. Transfusion-related mortality: The ongoing risks of allogenic blood transfusion and the available strategies for their prevention.  Blood. 2009; 113: 3406-3417.
  • Hellings S, Blajchman MA. Transfusion-related immunosuppression. Anesthesia & Intensive Care Medicine. 2009; In Press.
  • Blajchman MA. Protecting the blood supply from emerging pathogens: The role of pathogen inactivation. Transfusion Clinique et Biologique. 2009; 16: 70-74.
  • Ainsworth CD, Crowther MA, Treleaven D, Evanovitch D, Webert KE, Blajchman MA. Severe haemolytic anemia post-renal transplantation produced by donor ani-D passenger lymphocytes: Case report and literature review. Transfus Med Rev. 2009; 23: 155-159.
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0